IDIOPATHIC INFLAMMATORY MYOPATHY
Clinical trials for IDIOPATHIC INFLAMMATORY MYOPATHY explained in plain language.
Never miss a new study
Get alerted when new IDIOPATHIC INFLAMMATORY MYOPATHY trials appear
Sign up with your email to follow new studies for IDIOPATHIC INFLAMMATORY MYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take on autoimmune diseases in first human trial
Disease control Recruiting nowThis early-stage study tests a new treatment called ALLO-329 for people with lupus, myositis, or scleroderma. The therapy uses specially engineered immune cells from a healthy donor to target and calm overactive immune cells. The main goal is to check safety and find the right do…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated May 26, 2026 04:38 UTC
-
Engineered immune cells aim to tame rare muscle disorders
Disease control Recruiting nowThis study tests a new treatment called CABA-201 for people with active inflammatory myopathy, a group of rare diseases where the immune system attacks muscles. The treatment uses a patient's own immune cells, modified to target and destroy certain immune cells that cause the dis…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: PHASE2, PHASE3 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
Could CAR t cells tame autoimmune diseases? new trial begins
Disease control Recruiting nowThis early-phase study tests a new treatment called CC-97540, which uses a person's own immune cells (CAR T cells) to target and calm the overactive immune system in severe autoimmune diseases like lupus, myositis, scleroderma, and rheumatoid arthritis. The goal is to see if it i…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: PHASE1 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated May 18, 2026 12:11 UTC